A new multidisciplinary study conducted by researchers at the University of Rochester Medical Center has found that the co-development of three systems, the gut microbiome, respiratory system and ...

According to the terms of the agreement, Sanofi will acquire London-based Vicebio’s entire share capital for an upfront ...

Inspira is developing the ART device, a cost effective early extracorporeal respiratory support system with an intent to function as an “Artificial Lung” for deteriorating respiratory patients.

Study: Development of mRNA vaccines against respiratory syncytial virus (RSV). Image Credit: ART-ur/Shutterstock The single-stranded (ss) RNA virus, RSV, is the primary pathogen that causes ...

Sanofi SA (NASDAQ:SNY) on Tuesday agreed to acquire Vicebio Ltd, a privately held biotechnology company headquartered in ...

While mRNA vaccines have circumvented the risk of enhanced respiratory disease, which had plagued early vaccine development efforts, the phase I clinical trials in humans have reported lower T ...

We are currently experiencing a renaissance in the treatment landscape for respiratory disease, but we can do better. When I first began my career in drug development more than 20 years ago, I had ...

The Novo Nordisk Foundation, the philanthropic arm of the Danish pharmaceutical giant, announced Dec. 18 that it has committed $260 million toward the development and improvement of respiratory ...